LUGANO, Switzerland, March 7, 2017 /PRNewswire/ --

ESMO, the leading European organisation for medical oncology, announced it will take over the organisation of the Targeted Anticancer Therapies (TAT) Congress, with the aim of expanding its educational offer and ensure that professionals are kept up-to-date with the latest drug developments to improve outcomes for cancer patients.

Starting in 2018, the TAT Congress , considered the "home of phase 1 in oncology," will take place annually in Europe, with next year's congress organised in March in Paris, France.

"Early drug development in oncology is undergoing a revolution," said Jean-Charles Soria, TAT Scientific Chair, Drug Development Department, Gustave Roussy, Paris, France. "Phase-1 trials are no longer the exclusive domain of highly specialised investigators and scientists but a field where academia, industry, clinicians, researchers, regulators, scientists discuss together to speed up the development of new anti-cancer treatment for the benefit of cancer patients."

"The role of early-phase trials in oncology drug development has changed dramatically with the advent of precision medicine," said ESMO President Fortunato Ciardiello. "ESMO is committed to organise educational activities that provide comprehensive updates on the latest developments, be it in clinical practice or earlier phases of development. It is only natural for ESMO to include such a fundamental event in our educational offer providing an expanded programme as well as a broader experience to attendees."

"TAT offers a top-quality programme, covering the most promising new drugs and targets under development in early-phase clinical and translational research, as well as drugs close to entering clinical development," explained Josep Tabernero, ESMO President-Elect, TAT 2017 Organising Committee. "If you want to know what your clinical practice is going to be like in five-10 years, this is the meeting to attend."

Full story: http://bit.ly/2lRynsV

ESMO is the leading professional organisation for medical oncology, with over 15,000 members representing oncology professionals from over 130 countries worldwide.

ESMO Press Office
media@esmo.org
+41(0)91-973-19-07

SOURCE European Society for Medical Oncology (ESMO)